BioHarvest Sciences Advances Partnership with Pharmaceutical Company, Transitioning to Stage Two of CDMO Deal

BioHarvest Sciences has advanced to stage two of its partnership with a major pharmaceutical company, marking a key milestone in the development of plant-derived biological materials for use in approved drugs. Stage one involved identifying and working with specific plant cells to produce targeted phyto-medicinal compounds in solid media using petri dishes. Stage two involves cultivating these cells in liquid media within small-scale bioreactors, a significant step toward commercial scalability. The transition to stage two is a validation of the company's work and a strong endorsement of its mission to develop life-changing plant compounds that promote health and wellness.

Rehovot, Israel -- BioHarvest Sciences Inc. (NASDAQ: BHST) has successfully transitioned to Stage 2 in its CDMO contract with a Nasdaq-listed pharmaceutical company, marking a significant milestone in the development of plant-derived biological materials for use in approved drugs [1].

Stage 1 of the contract, which began in early 2024, focused on sourcing specific plant cells to develop a compound used in an approved drug product. The completion of Stage 1 indicates that BioHarvest's research team successfully isolated the cells of the target plant and mirrored, magnified, and multiplied those cells in petri dishes using the company's proprietary Botanical Synthesis platform [1].

Stage 2 involves the delivery of a sufficient amount of biomass to be tested for suitability and the development of optimal growing conditions in liquid media. This phase is crucial as it paves the road for potential future volume manufacturing and commercial production [1].

Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, commented, "This marks the first CDMO project to advance to Stage Two, and we are excited to continue working with a valued pharmaceutical partner on a high-impact therapeutic drug product. This milestone validates the versatility of our Botanical Synthesis platform to deliver scalable, cost-effective alternatives to traditional compound sourcing" [1].

Dr. Zaki Rakib, Chairman and President of the CDMO Division, added, "Stage One carried the highest technical risk, requiring extensive AI-assisted research. Completing it successfully proves our platform can address a broad range of molecule families. Stage Two will focus on scaling biomass and refining compound concentration, and carries a much higher probability of success. Importantly, this project sharpened our analytical capabilities and validated our in-house AI tools, which will now support all future CDMO engagements" [1].

BioHarvest Sciences is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds without the need to grow the underlying plant. The company is utilizing its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a CDMO for customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products [1].

The advancement to Stage 2 is a validation of BioHarvest's work and a strong endorsement of its mission to develop life-changing plant compounds that promote health and wellness. The company's proprietary technology and expertise in plant-based compound development position it as a key player in the pharmaceutical industry.

References:
[1] https://www.biospace.com/press-releases/bioharvest-announces-completion-of-stage-1-development-for-cdmo-contract-with-nasdaq-listed-pharmaceutical-company